- €20.66bn
- €53.04bn
- €46.61bn
- 37
- 65
- 63
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.56 | ||
| PEG Ratio (f) | 0.11 | ||
| EPS Growth (f) | 66.2% | ||
| Dividend Yield (f) | 2.15% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 4.5 | ||
| Price to Sales | 0.44 | ||
| EV to EBITDA | 12.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.09% | ||
| Return on Equity | -7.87% | ||
| Operating Margin | -0.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 41,400 | 44,081 | 50,739 | 47,637 | 46,606 | 46,443.27 | 47,152.49 | 1.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +84.94 | -21.13 | -68.23 | +122.25 | +6.96 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on seeds, improved plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others.
Directors
- Norbert Winkeljohann CSU (63)
- Werner Baumann CMG (58)
- Oliver Zuehlke VSU (52)
- Wolfgang Nickl CFO (51)
- Liam Condon MGB (53)
- Sarena Lin MGB (49)
- Stefan Oelrich MGB (52)
- Heiko Schipper MGB (51)
- Paul Achleitner IND (64)
- Simone Bagel-Trah IND (52)
- Norbert Bischofberger IND (65)
- Ertharin Cousin IND (61)
- Thomas Elsner IND (62)
- Johanna Faber IND (51)
- Colleen Goggins IND (66)
- Robert Gundlach IND (63)
- Heike Hausfeld IND (55)
- Reiner Hoffmann IND (65)
- Frank Loellgen IND (59)
- Wolfgang Plischke IND (69)
- Petra Reinbold-Knape IND (61)
- Michael Schmidt-Kiessling IND (61)
- Andre van Broich IND (50)
- Otmar Wiestler IND (64)
- Horst Baier SUB (64)
- Andrea Sacher SUB (39)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 15th, 1952
- Public Since
- November 28th, 1997
- No. of Employees
- 92,815
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Frankfurt Stock Exchange- Shares in Issue
- 982,424,082
- Address
- Kaiser-Wilhelm-Allee 1, LEVERKUSEN, 51373
- Web
- https://www.bayer.com/
- Phone
- +49 214301
- Contact
- Jost Reinhard
- Auditors
- Deloitte GmbH
Upcoming Events for BAYN
Dividend For BAYGn.DE - 0.1100 EUR
Dividend For BAYm.BA - 0.0367 EUR
Dividend For BAYRY.PK - 0.0304 USD
Q1 2025 Bayer AG Earnings Release
Q1 2025 Bayer AG Earnings Call
Bayer Crop Science Investor Webinar
Q2 2025 Bayer AG Earnings Release
Similar to BAYN
Apontis Pharma AG
Frankfurt Stock Exchange
CoDon AG
Frankfurt Stock Exchange
FAQ
What is the Bayer AG share price?
As of Today at 19:32 UTC, shares in Bayer AG are trading at €21.05. This share price information is delayed by 15 minutes.
How has the Bayer AG share price performed this year?
Shares in Bayer AG last closed at €21.05 and the price had moved by -20.1% over the past 365 days. In terms of relative price strength the Bayer AG share price has underperformed the FTSE Global All Cap Index by -21.51% over the past year.
What are the analyst and broker recommendations for Bayer AG?
The overall consensus recommendation for Bayer AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bayer AG dividend yield?
The Bayer AG dividend yield is 0.52% based on the trailing twelve month period.
Does Bayer AG pay a dividend?
Last year, Bayer AG paid a total dividend of €0.11, and it currently has a trailing dividend yield of 0.52%.Looking ahead, shares in Bayer AG are due to go ex-dividend on 2025-04-28 and the next dividend pay date is 2025-04-30.
When does Bayer AG next pay dividends?
Bayer AG are due to go ex-dividend on 2025-04-28 and the next dividend pay date is 2025-04-30. The historic dividend yield on Bayer AG shares is currently 0.52%.
How do I buy Bayer AG shares?
To buy shares in Bayer AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bayer AG?
As of the previous close price of €21.05, shares in Bayer AG had a market capitalisation of €20.66bn.
Where are Bayer AG shares listed?
Here are the trading details for Bayer AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: BAYN
What kind of share is Bayer AG?
Based on an overall assessment of its quality, value and momentum Bayer AG is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bayer AG share price forecast for 2025?
The analyst consensus target price for shares in Bayer AG is €27.00. That is 28.27% above the last closing price of €21.05.
Analysts covering Bayer AG currently have a consensus Earnings Per Share (EPS) forecast of €4.52 for the next financial year.
Find out moreWhat is the trend in the Bayer AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bayer AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -18.43%.
As of the last closing price of €21.05, shares in Bayer AG were trading -11.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bayer AG PE Ratio?
The Bayer AG PE ratio based on its reported earnings over the past 12 months is 4.56. The shares last closed at €21.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bayer AG?
Bayer AG's management team is headed by:
- Norbert Winkeljohann - CSU
- Werner Baumann - CMG
- Oliver Zuehlke - VSU
- Wolfgang Nickl - CFO
- Liam Condon - MGB
- Sarena Lin - MGB
- Stefan Oelrich - MGB
- Heiko Schipper - MGB
- Paul Achleitner - IND
- Simone Bagel-Trah - IND
- Norbert Bischofberger - IND
- Ertharin Cousin - IND
- Thomas Elsner - IND
- Johanna Faber - IND
- Colleen Goggins - IND
- Robert Gundlach - IND
- Heike Hausfeld - IND
- Reiner Hoffmann - IND
- Frank Loellgen - IND
- Wolfgang Plischke - IND
- Petra Reinbold-Knape - IND
- Michael Schmidt-Kiessling - IND
- Andre van Broich - IND
- Otmar Wiestler - IND
- Horst Baier - SUB
- Andrea Sacher - SUB